RenovoRx (RNXT) Stock: Why The Price Surged Over 130% Today

By Amit Chowdhry ● Nov 10, 2021
  • The stock price of RenovoRx Inc (NASDAQ: RNXT) increased by over 130% during intraday trading today. This is why it happened.

The stock price of RenovoRx Inc (NASDAQ: RNXT) – a biopharmaceutical company and innovator in targeted cancer therapy – increased by over 130% during intraday trading today. Investors are responding positively to RenovoRx announcing its novel therapy platform RenovoTAMP (RenovoRx Trans-Arterial Micro-Perfusion) will be highlighted during a presentation by expert panelist, Dr. Ripal Gandhi, at the Miami Cancer Institute’s New Advances in the Management of Pancreatic Cancer CME course this evening.

Dr. Gandhi – a Principal Investigator in RenovoRx’s ongoing Phase 3 TIGeR-PaC study and Professor of Interventional Radiology at the Miami Cancer Institute and Miami Cardiac and Vascular Institute, Florida International University Herbert Wertheim College of Medicine – will describe the results from initial clinical studies of RenovoTAMP used in combination with radiation therapy and its benefits when managing patients with stage 3 locally advanced pancreatic cancer (LAPC). And Dr. Gandhi will also review the key stages of the TIGeR-PaC protocol which uses RenovoTAMP for the intra-arterial delivery of gemcitabine, an approved chemotherapeutic agent, to treat unresectable LAPC.

In order to highlight a critical difference between intravenous (IV) and intra-arterial (IA) chemotherapy, Dr. Gandhi will present pharmacokinetic data, or data describing the drug absorption/distribution/metabolism/excretion of gemcitabine from five patients in the Phase 3 TIGeR-PaC study that received intra-arterial gemcitabine. The data demonstrates an approximately two-thirds reduction in systemic gemcitabine when compared to systemic levels in patients traditionally receiving IV infusion of gemcitabine.

A copy and recording of Dr. Gandhi’s presentation – titled “Potential Future Innovative Strategy for Pancreatic Cancer: Intra-Arterial Chemotherapy” – will be available on RenovoRx’s website.

KEY QUOTE:

“This innovative therapy platform is enabling the targeted treatment of inoperable LAPC with decreased side effects typical of systemic chemotherapy, while shifting the focus to what is most important to our patients: improving quality of life and allowing them to spend more time with their family and loved ones. RenovoTAMP, when used in combination with radiation therapy, is designed to reduce arterial microvasculature, thereby minimizing leakage during drug delivery and enhancing drug delivery directly to the tumor.”

— Dr. Gandhi

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.